BillionToOne, Inc.
Rank #237HypergrowthBLLN · Nasdaq · Healthcare
BillionToOne, Inc. (BLLN) — Rank #237 by gross profitability (GP/assets 0.29) · ROE 1.4% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0002070849 · all metrics point-in-time as of the filing date.
About
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
Show moreShow less
The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc.
was incorporated in 2016 and is headquartered in Menlo Park, California.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- State
- DE
- Filer Category
- Non-accelerated filerEmerging growth company
- Fiscal Year End
- December 31
- Website
- billiontoone.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowstable
- Gross marginstable
- Gross profitabilitystable
- Net cashstable
- Operating marginstable
- Return on equitystable
- Share count (dilution)stable
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-11 | 2024-12-31filed 2026-03-11 | 2023-12-31filed 2026-03-11 |
|---|---|---|---|
| Income statement | |||
| Revenue | 305.1 | 152.6 | 71.7 |
| Revenue growth (YoY) | 100.0% | 100.0% | 100.0% |
| Gross profit | 208.5 | 208.5 | 208.5 |
| Gross margin | 68.3% | 68.3% | 68.3% |
| Net income | 7.5 | (41.6) | (82.7) |
| Net margin | 2.4% | 2.4% | 2.4% |
| EPS (diluted) | $0.14 | -$4.12 | -$8.45 |
| EPS growth (YoY) | 103.4% | 51.2% | — |
| Cash flow | |||
| Operating cash flow | 24.6 | (41.4) | (53.7) |
| Capital expenditures | 8.9 | — | — |
| Free cash flow | 15.7 | 15.7 | 15.7 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?